Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart Failure

NACompletedINTERVENTIONAL
Enrollment

700

Participants

Timeline

Start Date

August 28, 2013

Primary Completion Date

March 19, 2020

Study Completion Date

March 31, 2022

Conditions
Ischemic Cardiomyopathy
Interventions
PROCEDURE

Percutaneous Coronary Intervention

DRUG

Drug Therapy for Heart Failure

The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines

DEVICE

Device Therapy for Heart Failure

The optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy.

Trial Locations (40)

RG24 9NA

Basingstoke and North Hampshire Hospital, Basingstoke

BT12 6BA

Royal Victoria Hospital, Belfast

B9 5SS

Birmingham Heartlands Hospital, Birmingham

FY3 8NR

Blackpool Victoria Hospital, Blackpool

LL18 5UJ

North Wales Cardiac Centre, Bodelwyddan

BH7 7DW

Royal Bournemouth Hospital, Bournemouth

BS2 8HW

Bristol Heart Institute, Bristol

CV2 2DX

University Hospital Coventry, Coventry

DT1 2JY

Dorset County Hospital, Dorchester

DD1 9SY

Ninewells Hospital, Dundee

EH16 4SA

Royal Infirmary of Edinburgh, Edinburgh

EX2 5DW

Royal Devon and Exeter Hospital, Exeter

G81 4DY

Golden Jubilee National Hospital, Glasgow

NN16 8UZ

Kettering General Hospital, Kettering

LS1 3EX

Leeds General Infirmary, Leeds

LE3 9QP

Glenfield Hospital, Leicester

L14 3PE

Liverpool Heart and Chest Hospital, Liverpool

EC1A 7BE

Barts Heart Centre, London

NW3 2QG

Royal Free Hospital, London

SE1 7EH

Guy's and St Thomas' Hospital, London

SE5 9RS

King's College Hospital, London

SW17 0QT

St George's Hospital, London

M13 9WL

Manchester Royal Infirmary, Manchester

TS4 3BW

The James Cook University Hospital, Middlesbrough

NE7 7DN

Freeman Hospital, Newcastle

OL1 2JH

Royal Oldham Hospital, Oldham

PL6 8DH

Derriford Hospital, Plymouth

PO6 3LY

Queen Alexandra Hospital, Portsmouth

SP2 8BJ

Salisbury District Hospital, Salisbury

S5 7AU

Northern General Hospital, Sheffield

SO16 6YD

Southampton General Hospital, Southampton

SG1 4AB

Lister Hospital, Stevenage

SR4 7TP

Sunderland Royal Hospital, Sunderland

SN3 6BB

Great Western Hospital, Swindon

WF1 4DG

Pinderfields Hospital, Wakefield

WV10 0QP

New Cross Hospital, Wolverhampton

WR5 1DD

Worcestershire Royal Hospital, Worcester

BN11 2DH

Worthing Hospital, Worthing

M23 9LT

Wythenshawe Hospital, Wythenshawe

YO31 8HE

York Hospital, York

All Listed Sponsors
collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

collaborator

London School of Hygiene and Tropical Medicine

OTHER

collaborator

University of York

OTHER

collaborator

Guy's and St Thomas' NHS Foundation Trust

OTHER

lead

King's College London

OTHER

NCT01920048 - Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart Failure | Biotech Hunter | Biotech Hunter